BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100actual
Sites
19
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-11 | actual | When the study began enrolling |
| Primary completion | 2025-06-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Muscle- Invasive Bladder Cancer
Interventions
- Biological: Durvalumab
- Biological: BCG
Primary outcome
what the primary-completion date above is the date OFIncidence of Grade 3 or 4 Possibly related adverse events (PRAEs)
measured From the date of the first dose of study treatment (Day 1) until 6 months after the initiation of study treatment
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed